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OBJECTIVES The goal of this work was to determine whether the blockade of histamine H2 receptors is
beneficial for the pathophysiology of chronic heart failure (CHF).
BACKGROUND Because CHF is one of the major life-threatening diseases, we need to find a novel effective
therapy. Intriguingly, our previous study, which predicts the involvement of histamine in
CHF, suggests that we should test this hypothesis in patients with CHF.
METHODS We selected 159 patients who received famotidine among symptomatic CHF patients for the
retrospective study. We blindly selected age- and gender-matched CHF patients receiving
drugs for gastritis other than histamine H2 receptor blockers as a control group. For the
prospective study, 50 symptomatic CHF patients were randomly divided into 2 groups. One
group received famotidine of 30 mg/day for 6 months, and the other group received
teprenone.
RESULTS In the retrospective study, famotidine of 20 to 40 mg decreased both left ventricular
end-diastolic and end-systolic lengths (LVDd and LVDs, respectively) and the plasma
B-type natriuretic peptide (BNP) levels (182  21 vs. 259  25 pg/ml, p  0.05) with
unaltered fractional shortening (FS). In a randomized, open-label study, compared with
teprenone, famotidine of 30 mg prospectively decreased both New York Heart Association
functional class (p  0.05) and plasma BNP levels (183  26 pg/ml vs. 285  41 pg/ml, p
 0.05); this corresponded to decreasing both LVDd (57  2 mm vs. 64  2 mm, p  0.05)
and LVDs (47 2 mm vs. 55 2 mm, p 0.05) with unaltered FS (15 1% vs. 17 1%).
The frequency of readmission because of worsening of CHF was lower in the famotidine
group (4% and 24%, p  0.05). On the other hand, teprenone had no effects on CHF.
CONCLUSIONS Famotidine improved both cardiac symptoms and ventricular remodeling associated with
CHF. Histamine H2 receptor blockers may have therapeutic benefits for CHF. (J Am Coll
ublished by Elsevier Inc. doi:10.1016/j.jacc.2006.05.069Cardiol 2006;48:1378–84) © 2006 by the American College of Cardiology Foundation
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vespite current medical therapy for patients with chronic
eart failure (CHF) such as angiotensin-converting enzyme
ACE) inhibitors or beta-adrenergic receptor blockers (1),
HF remains one of the major causes of high morbidity and
ortality worldwide. Chronic heart failure is characterized
y cardiac symptoms, impaired cardiac performance, cardiac
See page 1385
echanical stress, and neurohormonal imbalance (2). In-
eed, increased levels of catecholamines, cytokines, and
ngiotensin II are thought to play important roles in the
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nd Welfare, Japan, and a grant from the Japan Cardiovascular Research Foundation.
he funding sources had no involvement in the current study.H
Manuscript received April 11, 2006; revised manuscript received May 18, 2006,
ccepted May 23, 2006.athophysiology and development of CHF (3,4). Histamine
s one of the neurohormonal factors that provoke various
ellular functions via stimulation of histamine H1-H3 re-
eptors (5,6). Specifically, because histamine H2 receptors
re known to be located in gastric cells and enhance the
roduction of acids that cause gastric ulcers, the blocker of
istamine H2 receptors is developed as the drug for the
reatment of gastric ulcers (7). Interestingly, we have pre-
iously predicted that histamine H2 receptor blockers may
e cardioprotective in patients with CHF using the data
ining technique (8). The histamine H2 receptor is also
ocated in the cardiomyocytes, and this receptor is coupled
o Gs protein as well as is the beta receptor (9–13). Indeed,
t is reported that: 1) histamine provokes positive inotropic
ffects (11,14); and 2) the blocker of histamine H2 receptors
ecreases cardiac output (14). The important roles of mast
ells and released histamine are also accepted in the cardio-
ascular system (15).
We tested the hypothesis that the blockade of histamine
2 receptors by famotidine is beneficial for the pathophys-
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tudies.
ETHODS
his study was approved by the ethical committee of National
ardiovascular Center. Informed consent was obtained from
ll patients before participation in this study in accordance with
nstitutional approved protocols.
tudy population and protocols. THE RETROSPECTIVE
TUDY. A total of 1,104 consecutive subjects who were
dmitted to our hospital for treatment of CHF between
anuary 2002 and April 2004 were candidates for this study.
he criteria for enrollment in this study were: 1) clinical
vidence of heart failure despite the conventional therapy;
nd 2) left ventricular fractional shortening (FS) below 30%,
s assessed by 2-dimensional echocardiography. All the
atients had New York Heart Association (NYHA) func-
ional classifications of II to III, but were stable for 2
onths after their discharge. Among these patients, we
elected the patients who received famotidine of 20 to 40
g (n  159, the famotidine group). In the control group,
he patients were selected so as to be matched for age,
ender, and the cause of CHF (n  159). We randomly
elected age-, gender-, and cause-matched patients for the
ther drug of non-histamine H2 blocker for gastritis (n 
59). Among the 159 patients in each group, the number of
atients who suffered from dilated cardiomyopathy, hyper-
ensive heart disease, ischemic cardiomyopathy, and valvular
eart disease were 71, 11, 39, and 38, respectively. Clinical
arameters of the plasma brain natriuretic peptide (BNP)
evels and echocardiography were obtained. We estimated
he NYHA functional classification of each patient by 3
ndependent cardiologists who were blinded to the medical
reatment of CHF. If the estimations of all 3 doctors did not
gree, we decided to take the median among 3 values of
YHA functional classification.
The prospective studies: the effects of famotidine. We studied
0 patients with symptomatic CHF and gastroesophageal
eflux disease (GERD) in our institute. Gastroesophageal
eflux disease was diagnosed by questionnaires reported
reviously (16). The criteria for enrollment in this study
ere clinical evidence of heart failure despite the conven-
ional therapy and a left ventricular FS below 30%, as
Abbreviations and Acronyms
ACE  angiotensin-converting enzyme
AMP  adenosine monophosphate
BNP  brain natriuretic peptide
CHF  chronic heart failure
FS  fractional shortening
GERD  gastroesophageal reflux disease
LVDd  left ventricular end-diastolic volume
LVDs  left ventricular end-systolic volume
NYHA  New York Heart Associationssessed by 2-dimensional echocardiography, and existence ff GERD. All the patients had NYHA functional classifi-
ations of II to III. There were 32 men and 18 women with
mean age of 65 years. The number of patients diagnosed
s CHF because of dilated cardiomyopathy, hypertensive
eart disease, ischemic cardiomyopathy, and valvular heart
isease were 17, 2, 4, and 2 in each group, respectively.
xclusion criteria included chronic obstructive pulmonary
isease, pregnancy, and severe liver disease as defined by
aving hepatic enzymes 2 times the upper limit of normal
alues. All patients were treated by optimal and stable doses
f beta-blockers and ACE inhibitors for at least 3 months
efore screening echocardiography and randomization. We
id not change the doses of these drugs after the enrollment.
atients were randomly divided into 2 treatment groups:
amotidine (n  25, the famotidine group) and teprenone
n  25, the control group). The doses of famotidine and
eprenone were 30 and 150 mg per day, respectively, and
here were no patients who discontinued the intake of either
amotidine or teprenone, and drugs for CHF.
In the current study, we tested the hypothesis that
amotidine, the histamine H2 receptor blocker, may have
herapeutic benefits for CHF in the clinical settings. The
rimary end point is to assess the changes in NYHA
unctional class and the plasma BNP levels from the
aseline to 24 weeks. We estimated the NYHA functional
lassification of each patient by 3 independent cardiologists
ho were blinded to the treatment assignment of famoti-
ine. If the estimations of all 3 doctors did not agree,
e decided to take the median among 3 values of
YHA functional classification. Additional analyses were
one using the echocardiogram to obtain the changes in
eft ventricular or atrial volume, and the pressure differences
cross the tricuspid valve from baseline to 24 weeks.
urthermore, the frequency of readmission because of wors-
ning of CHF within 24 weeks was investigated.
Estimating from retrospective study results showing that
he reduction of the plasma BNP levels was about 30%, 25
atients were required for each study group. A randomiza-
ion was performed according to a computer generated
andomization list by central telephone call or fax to Clinical
tudy Support Center Japan (Suita Osaka, Japan).
Effects of teprenone. There is a possibility that teprenone
as deleterious effects on the pathophysiology of CHF, and
f this were the case, famotidine would appear to be
eneficial, when famotidine has no cardioprotective effects.
o examine this possibility, we administered teprenone to
0 patients with CHF for 24 weeks, and compared 10 CHF
atients without the teprenone treatment. The criteria for
he enrollment, evaluated parameters, and the evaluation
rocedure were the same as in the study of famotidine
escribed earlier in the text.
nalysis of parameters for CHF. Blood samples were
ollected in test tubes containing ethylenediaminetetraacetic
cid at baseline and after 24 weeks of the treatment. The
lasma was separated from blood cells by centrifugation and
rozen at 80°C. Plasma concentrations of BNP were
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Histamine and Heart Failure October 3, 2006:1378–84easured using a specific immunoradiometric assay (17).
he personnel performing these assays were blinded to the
atients’ treatment assignments.
M-mode echocardiography was performed with
-dimensional monitoring using a Sono layer phased-array
ector scanner (SONOS 5500, Hewlett Packard, Palo Alto,
alifornia) before and after 24 weeks of the treatment with
amotidine or teprenone (18). All echocardiograms were
ead by the same physician, at baseline and after 24 weeks of
he treatment, who was blinded to patients’ treatment,
ssignment, and time point.
tatistical analysis. Data are presented as mean  SEM.
tatistical analysis was performed using paired or unpaired
test for numerical values, and either chi-square tests or
ilcoxon signed rank test for categorical values. B-type
atriuretic peptide levels were logarithmically transformed
o perform the statistical analysis. Furthermore, we used
wo-way repeated-measures analysis of variance when we
ompared the changes of each parameter in 2 groups. The
hi-square tests were also performed to test the differences
f the incidence of the readmission. All statistical analyses
ere performed using Stat View version 5.0 for Windows
SAS Institute, Cary, North Carolina) and SPSS 10.0.5J
oftware (SPSS Inc., Chicago, Illinois).
able 1. Clinical Parameters of CHF With or Without
amotidine
Control
Group
(n  159)
Famotidine
Group
(n  159)
ge (yrs) 66  1 66  1
/F gender (%) 97/62 (61/39) 97/62 (61/39)
ypertension (%) 11 (7) 11 (7)
uration of CHF (yrs) 8.7  0.7 8.5  0.8
ystolic blood pressure (mm Hg) 112  9 105  8*
iastolic blood pressure (mm Hg) 67  4 62  5*
eart rate (beats/min) 73  5 66  5*
ractional shortening (%) 24  1 23  1
V diastolic diameter (mm) 58  2 54  1*
V systolic diameter (mm) 44  1 41  1*
A diameter (mm) 40  3 39  3
ressure across tricuspid valve (mm Hg) 30  2 28  2
lasma BNP levels (pg/ml) 259  25 182  21*
YHA functional class: II/III (%) 75/84 (47/53) 97/62 (61/39)*
oncomitant drugs, n (%)
Digoxin 126 (80) 134 (84)
Diuretics except spironolactone 140 (88) 137 (86)
Nitrates 80 (25) 32 (20)
Beta-blockers 143 (90) 137 (86)
ACE inhibitors 127 (80) 121 (76)
ARB 118 (20) 38 (24)
Spironolactone 25 (20) 25 (20)
alues are either numbers of each group, range, or mean  SEM. *p  0.05 vs. the
ontrol group.
ACE  angiotensin-converting enzyme; ARB  angiotensin receptor blocker;
NP  brain natriuretic peptide; CHF  chronic heart failure; LA  left atrium;
V  left ventricular; NYHA  New York Heart Association; Fractional shorteningH
%) (left ventricle end-diastolic diameter left ventricle end-systolic diameter)/left
entricle end-diastolic diameter.ESULTS
fter age and gender matching, as shown in Table 1, the
ender ratio and the average age of the 2 groups were
imilar. There were no significant differences of the variety
f medical treatment drugs between the 2 groups. Blood
ressure, heart rate, NYHA functional class, the plasma
NP levels, and left ventricular dimensions were smaller in
he famotidine group compared with the control group.
here were no differences between FS in the 2 groups. This
esult suggests that famotidine may be beneficial for patho-
hysiology of CHF.
As for the prospective randomized famotidine treatment
rotocol, medications were well tolerated over the 24-week
eriod. The participants were recruited from September
004 to October 2004. Participants attended clinic visits at
he time of randomization (baseline) and at 4- to 8-week
ntervals for 24 weeks. All patients completed the protocol
50 of 50). No patients died during the 24-week study. In
ddition, the doses of beta-blockers, ACE inhibitors, and
iuretics were not altered during the course of the entire
tudy.
There were no differences in age, gender, or concurrent
edications between the control and famotidine groups
Table 2). Blood pressure and heart rate were not different
etween the groups with and without famotidine before the
reatment. Famotidine administration slightly decreased
lood pressure (systolic and diastolic blood pressure 107 
mm Hg vs. 112  3 mm Hg, p  0.01 and 60  3 mm
able 2. Baseline Characteristics of the Study Population
Teprenone
Group
(n  25)
Famotidine
Group
(n  25)
ge (yrs) 65  2 65  2
/F gender (%) 16/9 (64/36) 16/9 (64/36)
YHA functional class: II/III (%) 8/17 (32/68) 10/15 (40/60)
ypertension (%) 4 (16) 6 (24)
uration of CHF (yrs) 11.2  1.7 13.2  2.3
ystolic blood pressure (mm Hg) 113  3 112  3
iastolic blood pressure (mm Hg) 68  3 67  2
eart rate (beats/min) 83  3 83  2
ractional shortening (%) 15  1 15  1
V diastolic diameter (mm) 65  2 64  2
V systolic diameter (mm) 55  2 55  2
A diameter (mm) 43  2 42  2
ressure across tricuspid valve (mm Hg) 33  3 36  3
lasma BNP levels (pg/ml) 268  28 286  41
oncomitant drugs, n (%)
Digoxin 24 (96) 22 (84)
Diuretics except spironolactone 25 (100) 25 (100)
Nitrates 7 (28) 4 (16)
Beta-blockers 25 (100) 25 (100)
ACE inhibitors 23 (92) 21 (84)
ARB 2 (8) 4 (16)
Spironolactone 10 (40) 8 (32)
alues are either numbers of each group, range, or mean  SEM.
Abbreviations as in Table 1.g vs. 67  2 mm Hg, p  0.05) and heart rate (79  2
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October 3, 2006:1378–84 Histamine and Heart Failurein1 vs. 83  2 min1, p  0.05), whereas the control
roup did not exhibit changes in either blood pressure
systolic and diastolic blood pressure 113  3 mm Hg vs.
13  3 mm Hg and 68  3 mm Hg vs. 68  3 mm Hg)
r heart rate (81  3 min1 vs. 83  3 min1) before and
4 weeks after the treatment. The patients who received
amotidine demonstrated improved functional capacity as-
essed by the plasma BNP levels and NYHA functional
igure 1. Changes in the plasma B-type natriuretic peptide (BNP) levels (A
nd after the treatment with (the famotidine group) or without famotidine
og transformation. The p values are obtained using 2-way repeated-meas
igure 2. Changes in left ventricular (LV) end-diastolic volume (LVDd) (
trial diameter (LAD) (D), and the pressure differences across the tricuspid valv
nd famotidine groups. The p values are tested using 2-way repeated-measureslass (Fig. 1). Plasma BNP level and NYHA functional class
ere unchanged after 24 weeks in the group without
amotidine. The functional improvement in the famotidine
roup was associated with improved cardiac performance.
ompared with the group without famotidine, the patients
reated with famotidine had lower left ventricular end-
iastolic volume (LVDd) and left ventricular end-systolic
olume (LVDs) while keeping FS unchanged (Fig. 2). The
New York Heart Association (NYHA) functional classification (B) before
control group). The plasma BNP levels are statistically analyzed after the
nalysis of variance (A) or Wilcoxon signed rank test (B).
end-systolic volume (LVDs) (B), LV fractional shortening (FS) (C), left) andA) or
e (TR dPmax) (E) before and after 24 weeks of treatment in the control
analysis of variance.
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Histamine and Heart Failure October 3, 2006:1378–84requency of readmission because of worsening of CHF was
ower in the famotidine group compared with the control
roup (1 [4%] and 6 [24%], difference [95% confidence
nterval] 20% [2 to 38], p  0.05).
As for the prospective randomized teprenone treatment
rotocol, medications were well tolerated over the 24-week
eriod. The participants were recruited from September
004 to October 2004. Participants attended clinic visits at
he time of randomization (baseline) and at 4- to 8-week
ntervals for 24 weeks. All patients completed the protocol
20 of 20). No patients died during the 24-week study. In
ddition, the doses of beta-blockers, ACE inhibitors, and
iuretics were not altered during the course of entire study.
here were no differences in age, gender, or concurrent
edications between the control and famotidine groups
Table 3). We found that teprenone does not affect the
everity of CHF (the plasma BNP levels: 246  48 pg/ml
s. 234  49 pg/ml, LVDd: 65.8  3.6 mm vs. 65.6 
.7 mm, LVDs: 53.2  2.9 mm vs. 53.8  3.6 mm, FS:
8.7  2.8% vs. 18.3  1.3% before and 24 weeks after an
dministration of teprenone) in comparison with the pa-
ients without the teprenone treatment (the plasma BNP
evels: 248  26 pg/ml vs. 238  18 pg/ml, LVDd: 65.1 
.3 mm vs. 66.7  1.5 mm, LVDs: 53.6  1.4 mm vs.
5.1  1.2 mm, FS: 17.7  1.3% vs. 17.2  1.0% at
bservation time of 0 and 24 weeks). The frequency of
eadmission because of worsening of CHF was identical
etween the teprenone and control groups (2 [20%] and
able 3. Baseline Characteristics of the Study Population
Teprenone
Group
(n  10)
No Treatment
Group
(n  10)
ge (yrs) 67  4 68  3
/F gender (%) 7/3 (70/30) 7/3 (70/30)
YHA functional class: II/III (%) 2/8 (20/80) 2/8 (20/80)
ypertension (%) 2 (20) 2 (20)
uration of CHF (yrs) 12.1  2.8 12.0  1.3
ystolic blood pressure (mm Hg) 109  5 114  4
iastolic blood pressure (mm Hg) 64  4 65  32
eart rate (beats/min) 75  4 75  2
ractional shortening (%) 18  3 18  1
V diastolic diameter (mm) 66  4 65  1
V systolic diameter (mm) 53  3 54  1
A diameter (mm) 45  2 45  2
ressure across tricuspid valve (mm Hg) 36  3 34  2
lasma BNP levels (pg/ml) 246  48 248  26
oncomitant drugs, n (%)
Digoxin 10 (100) 10 (100)
Diuretics except spironolactone 10 (100) 10 (100)
Nitrates 2 (20) 1 (10)
Beta-blockers 10 (100) 10 (100)
ACE inhibitors 9 (90) 7 (70)
ARB 0 (0) 3 (30)
Spironolactone 5 (50) 5 (50)
alues are either numbers of each group, range, or mean  SEM.
Abbreviations as in Table 1.[20%]). aISCUSSION
n the present study, we demonstrate that the blockade of
istamine H2 receptors favors the improvements of the
athophysiology of CHF via retrospective and prospective
linical trials. These conclusions propose the novel findings
hat histamine that stimulates histamine H2 receptors is one
f the neurohumoral factors for the worsening of CHF, and
hat the blockade of histamine H2 receptors becomes the
ovel strategy for the treatment of CHF.
istamine in failing hearts. We have shown that hista-
ine release is augmented in the ischemic myocardium
ompared with the non-ischemic myocardium in dogs
unpublished data). When the mast cells that store hista-
ine are stimulated by ischemia or mechanical stress, mast
ells actively release histamine. There are reports that mast
ells are found in the human heart (19) and have been
mplicated in cardiovascular diseases (15,20,21). Indeed, the
ncrease of mast cells have been observed in the hearts of
atients with hypertrophy (22), dilated cardiomyopathy,
schemic cardiomyopathy (23), and ischemia/reperfusion
24), and the infarction-related coronary arteries (25). Fur-
hermore, histamine is present in high concentrations in
ardiac tissues in most animal species, including humans
10,26,27), and its release from cardiac stores and the
ubsequent actions on the heart may be of importance in the
athophysiology of heart disease. These lines of evidence
gree with the present observation that the blockade of
istamine H2 receptors in failing hearts has an impact on
he pathophysiology of CHF.
he role of histamine receptors in failing hearts. The
istamine receptors (H1, H2, H3, and H4) are all G protein-
oupled molecules, and they transduce extracellular signals
ia Gq, Gs, and Gi/o, respectively (5,6,28). Specifically,
istamine H2 receptors are linked to Gs proteins that
acilitate the production of cyclic adenosine monophosphate
AMP) as beta-adrenoreceptors are (29). Histamine H2-
eceptor-stimulated cAMP accumulation or adenylyl cyclase
ctivator has been demonstrated in a variety of tissues
ncluding gastric cells (10,30), vascular smooth muscle cells
31), brain (10,32), and cardiac tissue (10,33). Beta-
drenoreceptor blockers are known to be cardioprotective in
ailing hearts because the accumulation of cyclic AMP after
he activation of beta-adrenoreceptors enhances both myo-
ardial contractility and oxygen consumption, which dete-
iorates heart function in patients with CHF (34,35). In
ddition, it has been reported that histamine is a powerful
asoconstrictor in atherosclerotic coronary arteries (36),
hich may locally provoke coronary spasm and thus con-
ribute to the onset of myocardial infarction (23). The
mportance of beta-adrenoreceptor blockers depends on the
resence of both catecholamine and beta-adrenoreceptors in
he heart. Therefore, because histamine H2 receptors and
istamine are located in failing human hearts, it is likely that
lockers of histamine H2 receptors are as cardioprotective
gainst failing hearts as beta-adrenoreceptor blockers are.
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October 3, 2006:1378–84 Histamine and Heart FailureBecause famotidine decreases both blood pressure and
eart rate, this may improve the pathophysiology of CHF.
ndeed, the reduction of afterload or preload and heart rate
eems to be an important factor in the treatment of CHF.
his is also the case in either beta-adrenoreceptor blockers
r ACE inhibitors in patients with heart failure. Either
eta-adrenoreceptor blockers or ACE inhibitors are still
ffective independent of the reduction of loading condition
o the heart, because they inhibit the signal transduction for
eterioration of cardiac function. Because histamine in-
reases cyclic AMP levels in the cardiomyocytes via
istamine H2 receptors, famotidine may be beneficial
hrough both load-reduction-dependent and -independent
echanisms.
linical importance. Beta-adrenoreceptor blockers have
een shown to be effective for treating ischemic heart
iseases and heart failure (37), and histamine receptor
lockers are similar to beta-adrenoreceptor blockers. Hista-
ine plays an important role in the regulation and mal-
egulation of cardiac and coronary function. Furthermore,
he histamine receptor blockers such as famotidine that are
sed for peptic ulcers or GERD all over the world could be
sed for ischemic heart diseases. Furthermore, beta-
drenoreceptor blockers ameliorate the severity of heart
ailure, and histamine receptor blockers may be beneficial
or patients with CHF. However, we should note that the 3
2 receptor blockers administered for 7 days at clinical
osages had no significant effect on left ventricular systolic
unction, aerobic metabolic performance, or exercise capac-
ty in men with class II or III stable CHF (38). This
uggests that a relatively long-term administration of hista-
ine receptor blockers is necessary to mediate the cardio-
rotective effects of histamine receptor blockers in patients
ith CHF as a relatively long-term administration of
eta-adrenoreceptor blockers is necessary for the treatment
f CHF (37).
Moreover, because famotidine was administered in addi-
ion to the aggressive treatments with beta-adrenoreceptors
lockers, ACE inhibitors, and diuretics, and we proved that
amotidine further improves the pathophysiology of CHF,
t is possible to develop famotidine for the drug of CHF,
lthough we need to plan and perform a large-scale clinical
rial for the investigation of the effects of famotidine on
HF. We also need to clarify the best dose of famotidine
or the treatment of CHF.
tudy limitations. The present study has several limita-
ions that we need to pay attention to. First of all, the first
art of the data was obtained from the retrospective analysis,
nd seemed to be influenced by many factors, although
able 1 showed low BNP levels and low ventricular volumes
n the famotidine group suggested the preventive effects
f famotidine on cardiac remodeling. To strengthen the
ypothesis obtained by the retrospective study, we per-
ormed the prospective analysis using either famotidine or
eprenone.The second limitation is that the second part of the study
as an open-labeled, randomized trial using small sampling
ize. However, to decrease these weaknesses, we used the
bjective end points such as the plasma BNP levels and left
entricular dimensions, and we also tried to exclude the
ubjective scope of the assessment of NYHA functional
lassification.
Third, the severities of pathophysiology of CHF in the
etrospective and prospective studies were different. The
everity of CHF in enrolled patients in prospective study is
igher than that in the retrospective study. This is because
e enrolled the patients from the different protocols. Nev-
rtheless, because both studies suggest that famotidine is
ffective for patients with CHF, we may be able to suggest
he beneficial effects of famotidine to treat patients with
HF.
Fourth, if teprenone could be deleterious to the patho-
hysiology of CHF, famotidine seemed to be beneficial
ompared with teprenone even if famotidine has no bene-
cial effects on CHF. Before planning the present study, we
ested the effects of pathophysiology of CHF, and we found
hat teprenone has no beneficial or deleterious effects on
HF in the present study.
Fifth, either famotidine or teprenone may directly affect the
lasma half-life or excretion of BNP. If this is the case, the
lasma BNP levels may be altered independent of
he improvements of CHF. We cannot deny this possibility,
owever, because left ventricular dimension becomes
maller in the famotidine group, suggesting that famotidine
s beneficial for the heart of CHF patients.
Sixth, we should notice that an interaction of gastritis
ith heart failure could confound their conclusion regarding
he effect of histamine blockade. Indeed, it may be still
ossible to consider that famotidine improves cardiac func-
ion via an improvement of GERD if GERD worsens
HF, because we have no positive or negative data to link
ERD and CHF. We should investigate this possibility to
xplain the effects of H2 receptor blockers on CHF in
urther study.
In summary, despite these limitations, we proposed the
ypothesis that H2 receptor blockers are effective for the
reatment of CHF, and we need to verify the beneficial
ffects of H2 receptor blockers such as ranitidine or
imetidine as well as famotidine in CHF patients with a
arge-scale trial.
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